Erythromycin hydrogen glutarate | 5442-22-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: Erythromycin hydrogen glutarate
• 英文别名: 5-[6-[[(3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-3,5,7,9,11,13-hexamethyl-2,10-dioxo-oxacyclotetradec-4-yl]oxy]-4-methoxy-2,4-dimethyloxan-3-yl]oxy-5-oxopentanoic acid
• CAS: 5442-22-8
• 化学式: C₄₂H₇₃NO₁₆
• 分子量: 848.0
• InChiKey: DLXKPWOBAXEREQ-JKMGMBDVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  59
• 可旋转键数：
  13
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  237
• 氢给体数：
  5
• 氢受体数：
  17

文献信息

• [EN] PRODRUG COMPOSITIONS AND METHODS OF TREATMENT<br/>[FR] COMPOSITIONS DE PROMÉDICAMENT ET PROCÉDÉS DE TRAITEMENT
  申请人：AQUESTIVE THERAPEUTICS INC

  公开号：WO2021087359A1

  公开（公告）日：2021-05-06

  Pharmaceutical compositions include a prodrug of epinephrine are described.

  药物组合物包括表述的肾上腺素前药。
• Methods and compositions using 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione for the treatment or prevention of cutaneous lupus
  申请人：Zeldis B. Jerome

  公开号：US20060270707A1

  公开（公告）日：2006-11-30

  Methods of treating, managing or preventing cutaneous lupus are disclosed. Specific methods encompass the administration of 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione alone or in combination with a second active agent. Pharmaceutical compositions and single unit dosage forms are also disclosed.

  本发明揭示了治疗、管理或预防皮肤红斑狼疮的方法。具体方法包括单独或与第二活性剂联合给药4-[(环丙烷羰胺基)甲基]-2-(2,6-二氧哌嗪-3-基)异吲哚-1,3-二酮。还揭示了药物组合物和单剂量单位剂型。
• Methods for treating cutaneous lupus using aminoisoindoline compounds
  申请人：Zeldis B. Jerome

  公开号：US20070155791A1

  公开（公告）日：2007-07-05

  Methods of treating cutaneous lupus in a human are disclosed. Specific methods encompass the administration of (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione (ACTIMID™), 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione (REVLIMID®), or cyclopropyl 2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindolin-4-yl}carboxamide, alone or alternatively, in combination with a second active agent.

  本发明揭示了治疗人类皮肤狼疮的方法。具体方法包括给予(+)-2-[1-(3-乙氧基-4-甲氧基苯基)-2-甲基磺酰乙基]-4-乙酰氨基异吲哚-1,3-二酮，4-(氨基)-2-(2,6-二氧代(3-哌啶基))-异吲哚-1,3-二酮（ACTIMID™），3-(4-氨基-1-氧代-1,3-二氢吲哚-2-基)-哌啶-2,6-二酮（REVLIMID®），或环丙基2-[(1S)-1-(3-乙氧基-4-甲氧基苯基)-2-(甲基磺酰基)乙基]-3-氧代异吲哚-4-基}羧酰胺，单独或与第二活性剂联合使用。
• METHODS FOR TREATING CUTANEOUS LUPUS USING AMINOISOINDOLINE COMPOUNDS
  申请人：Zeldis Jerome B.

  公开号：US20110104144A1

  公开（公告）日：2011-05-05

  Methods of treating cutaneous lupus in a human are disclosed. Specific methods encompass the administration of (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione (ACTIMID™), 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione (REVLIMID®), or cyclopropyl 2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindolin-4-yl}carboxamide, alone or alternatively, in combination with a second active agent.

  本发明揭示了治疗人类皮肤狼疮的方法。具体方法包括单独或与第二活性剂联合使用(+)-2-[1-(3-乙氧基-4-甲氧基苯基)-2-甲基磺酰基乙基]-4-乙酰氨基异吲哚啉-1,3-二酮，4-(氨基)-2-(2,6-二氧杂(3-哌啶基))-异吲哚啉-1,3-二酮（ACTIMID™），3-(4-氨基-1-氧代-1,3-二氢-异吲哚-2-基)-哌啶-2,6-二酮（REVLIMID®）或环丙基2-[(1S)-1-(3-乙氧基-4-甲氧基苯基)-2-(甲基磺酰基)乙基]-3-氧代异吲哚-4-基}羧酰胺。
• METHODS FOR TREATING DISEASES USING ISOINDOLINE COMPOUNDS
  申请人：Schafer Peter H.

  公开号：US20140187599A1

  公开（公告）日：2014-07-03

  Methods of treating a disease selected from dermatomyositis, prurigo nodularis, pyoderma gangrenosum, alopecia areata, hidradenitis suppurtiva, rosacea, lichen planus, giant cell arteritis, Sjogren's syndrome, gout, chronic prostatitis, posterior uveitis, vulvodynia and interstitial cystitis in a human are disclosed. Specific methods encompass the administration of (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, cyclopropyl 2-[(15)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindolin-4-yl}carboxamide or a combination thereof, or a pharmaceutically acceptable prodrug, metabolite, polymorph, salt, solvate or clathrate thereof.

  本发明公开了用于治疗人体中选择的疾病的方法，包括皮肌炎、结节性瘙痒、化脓性坏疽、斑秃、汗腺炎、酒渣鼻、扁平苔藓、巨细胞动脉炎、Sjogren综合症、痛风、慢性前列腺炎、后部葡萄膜炎、阴道疼痛和间质性膀胱炎。具体方法包括给予(+)-2-[1-(3-乙氧基-4-甲氧基苯基)-2-甲基磺酰基乙基]-4-乙酰氨基异吲哚啉-1,3-二酮、环丙基2-[(15)-1-(3-乙氧基-4-甲氧基苯基)-2-(甲基磺酰基)乙基]-3-氧代异吲哚啉-4-基}羧酰胺或其组合物，或其药物可接受的前药、代谢物、多晶型、盐、溶剂或包合物。